Group 1 - The core viewpoint of the news is that 港通医疗 (301515) has experienced a significant decline in its financial performance for the first three quarters of 2025, with a notable drop in both revenue and net profit compared to the previous year [2] - As of February 5, 2026, 港通医疗's stock closed at 25.69 yuan, reflecting a 1.22% increase, with a trading volume of 24,400 hands and a total transaction amount of 62.48 million yuan [1] - The company reported a main revenue of 344 million yuan for the first three quarters of 2025, a decrease of 30.06% year-on-year, and a net profit attributable to shareholders of -10.21 million yuan, down 150.92% year-on-year [2] Group 2 - In the third quarter of 2025, 港通医疗's single-quarter main revenue was 79.12 million yuan, showing a year-on-year increase of 42.81%, while the net profit attributable to shareholders was -1.80 million yuan, a decrease of 138.94% year-on-year [2] - The company's debt ratio stands at 40.94%, with an investment income of -179,400 yuan and financial expenses of 542,400 yuan, while the gross profit margin is reported at 22.45% [2] - The funding flow data indicates that on February 5, 2026, the net inflow of main funds was 375,200 yuan, accounting for 0.6% of the total transaction amount, while retail investors saw a net inflow of 557,760 yuan, representing 8.93% of the total transaction amount [1]
股票行情快报：港通医疗（301515）2月5日主力资金净买入37.52万元